logo

Advaxis Inc. (ADXS)



Trade ADXS now with
  Date
  Headline
7/6/2017 4:46:49 PM Advaxis Trading Expected To Resume At 5:00 PM ET
7/6/2017 4:31:21 PM Advaxis Trading Halted Pending News
4/19/2017 8:04:34 AM Advaxis Names Anthony Lombardo Chief Business Officer
3/7/2017 8:06:16 AM Advaxis Names Al Blunt VP Of Medical
3/6/2017 6:04:44 AM Advaxis Announces FDA Acceptance Of IND For Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
2/27/2017 8:08:42 AM Advaxis And SELLAS Announce Licensing Deal For Development Of WT1 Antigen-Targeting Immunotherapy
2/6/2017 8:07:30 AM Advaxis Announces First Patient Dosed In Global Phase 3 AIM2CERV Trial For High-risk, Locally Advanced Cervical Cancer
10/20/2016 7:35:53 AM Advaxis Begins Part B Of The KEYNOTE-046 Clinical Trial Evaluating ADXS-PSA In Combination With KEYTRUDA
10/3/2016 8:05:08 AM Advaxis Names Christopher Duke SVP And COO
8/16/2016 9:32:37 AM Advaxis Secures $30 Mln Direct Placement Financing To Healthcare Specialist Investors
8/11/2016 8:08:36 AM Advaxis Says Phase 2 Head And Neck Cancer Study With AXAL Advances To Second Stage
8/2/2016 8:04:51 AM Amgen Announces Global Agreement For Development, Commercialization Of Advaxis' ADXS-NEO
7/26/2016 8:13:18 AM Advaxis Combination Study Of AXAL With AstraZeneca’s Anti-PD-L1 Durvalumab Completes Second Dose-Escalation Cohort
7/21/2016 7:09:32 AM Advaxis: AXAL Gets FDA Fast Track Designation As Adjuvant Therapy For High-Risk Locally Adv. Cervical Cancer Patients